Compare PGC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGC | ANNX |
|---|---|---|
| Founded | 1921 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.7M | 873.3M |
| IPO Year | 1997 | 2020 |
| Metric | PGC | ANNX |
|---|---|---|
| Price | $44.68 | $4.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $40.50 | $16.50 |
| AVG Volume (30 Days) | 92.4K | ★ 2.7M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | ★ 13.51 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $282,995,000.00 | N/A |
| Revenue This Year | $32.39 | N/A |
| Revenue Next Year | $12.64 | $16,320.74 |
| P/E Ratio | $27.38 | ★ N/A |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $24.71 | $2.54 |
| 52 Week High | $49.14 | $7.18 |
| Indicator | PGC | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 39.34 |
| Support Level | $44.85 | $3.79 |
| Resistance Level | $47.32 | $5.63 |
| Average True Range (ATR) | 0.94 | 0.21 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 32.39 | 37.35 |
Peapack Gladstone Financial Corp is a bank holding company. Through its subsidiaries, the company offers various wealth management, investment banking, and commercial and personal banking solutions to its clients. The company has two reportable segments: Banking, which generates the maximum revenue, and Wealth Management. The Banking segment includes commercial, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; escrow management; deposit generation; operation of ATMs; telephone and internet banking services; credit card services, etc. The Wealth Management segment offers investment management services for individuals and institutions; personal trust services; and other financial planning and advisory services.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.